Jupiter Neurosciences (JUNS) Net Cash Flow (2023 - 2025)

Jupiter Neurosciences (JUNS) has reported Net Cash Flow for 3 consecutive years, with -$2.4 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 162.82% year-over-year to -$2.4 million in Q4 2025; TTM through Dec 2025 was -$5.4 million, a 244.71% decrease from a year earlier, with the FY2025 full-year figure at $19832.0, down 99.47% from the prior year.
• Net Cash Flow was -$2.4 million for Q4 2025 at Jupiter Neurosciences, down from -$1.2 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $3.8 million in Q4 2024 and troughed at -$2.4 million in Q4 2025.
• A 3-year average of -$189315.7 and a median of -$31137.0 in 2023 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 12205.4% in 2024 and sank 12767.82% in 2025, its largest moves.
• Over 3 years, Net Cash Flow stood at -$31137.0 in 2023, then jumped by 12205.4% to $3.8 million in 2024, then slumped by 162.82% to -$2.4 million in 2025.
• The last three Net Cash Flow figures came in at -$2.4 million (Q4 2025), -$1.2 million (Q3 2025), and -$828222.0 (Q2 2025), per Business Quant data.